Want to see SE:OSSD full AI Analyst Report?
OSSD Stock Chart & Stats
kr11.30
-kr0.12(-0.97%)
At close: 4:00 PM EST
kr11.30
-kr0.12(-0.97%)
Day’s Range― - ―
52-Week Rangekr3.34 - kr16.72
Previous CloseN/A
Volume95.81K
Average Volume (3M)297.02K
Market Cap
kr450.80M
Enterprise Valuekr294.75M
Total Cash (Recent Filing)kr170.48M
Total Debt (Recent Filing)kr1.16M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding110,625,916
10 Day Avg. Volume325,245
30 Day Avg. Volume297,022
Financial Highlights & Ratios
PEG Ratio3.08
Price to Book (P/B)4.04
Price to Sales (P/S)6.95
P/FCF Ratio-17.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)kr178.64M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and substantial equity provide a durable financial buffer that lowers refinancing risk and preserves strategic optionality. This balance-sheet strength supports continued investment in commercialization and clinical validation while the company works to reduce cash burn over the coming months.
High Gross MarginsExtremely high gross margins reflect advantaged product economics and pricing power in its implant portfolio. Those margins create structural room to absorb commercial and R&D costs and improve the probability of achieving operating leverage as sales scale, supporting durable profitability potential.
Historical Revenue ScalingMaterial multi-year revenue growth demonstrates successful product adoption and effective go-to-market execution across clinical customers and distribution partners. That underlying commercial traction is a durable foundation for future expansion if the company stabilizes margins and cash generation.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flow is a persistent structural weakness that erodes runway and increases reliance on external financing. Continued cash burn constrains the firm's ability to invest organically or scale sales support without dilution or additional funding over the next several months.
Persistent Operating LossesLarge negative EBIT and net margins indicate the company has not yet converted strong gross profits into operating profitability. Structural cost bases (commercial, clinical, R&D) remain high relative to revenue, meaning sustainable profitability will require either significant scale or cost reduction.
Recent Revenue DeclineA recent dip in TTM revenue undermines momentum from prior multi-year growth and raises execution risk. Slowing or volatile top-line trends make it harder to leverage high gross margins to cover fixed operating costs, complicating the path to stable cash generation and profitability.
OssDsign AB News
OSSD FAQ
What was OssDsign AB’s price range in the past 12 months?
OssDsign AB lowest stock price was kr3.33 and its highest was kr16.72 in the past 12 months.
What is OssDsign AB’s market cap?
OssDsign AB’s market cap is kr450.80M.
When is OssDsign AB’s upcoming earnings report date?
OssDsign AB’s upcoming earnings report date is Aug 18, 2026 which is in 48 days.
How were OssDsign AB’s earnings last quarter?
OssDsign AB released its earnings results on May 05, 2026. The company reported -kr0.1 earnings per share for the quarter, the consensus estimate of -kr0.1 by kr0.
Is OssDsign AB overvalued?
According to Wall Street analysts OssDsign AB’s price is currently Overvalued.
Does OssDsign AB pay dividends?
OssDsign AB does not currently pay dividends.
What is OssDsign AB’s EPS estimate?
OssDsign AB’s EPS estimate is -0.17.
How many shares outstanding does OssDsign AB have?
OssDsign AB has 110,625,916 shares outstanding.
What happened to OssDsign AB’s price movement after its last earnings report?
OssDsign AB reported an EPS of -kr0.1 in its last earnings report, expectations of -kr0.1. Following the earnings report the stock price went up 2.256%.
Which hedge fund is a major shareholder of OssDsign AB?
Currently, no hedge funds are holding shares in SE:OSSD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OssDsign AB
OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the United States, the United Kingdom, the wider European region, and other global territories. Its product line features OSSDSIGN cranial, a comprehensive implant and accessory system engineered for the reconstruction of skull defects in cranioplasty procedures. Another key offering, OSSDSIGN facial, is designed to correct skeletal deformities, whether they arise from trauma or are congenital. Additionally, OssDsign provides the OSSDSIGN Cranioplug, which serves to secure bone flaps and cover burr holes, and OssDsign Catalyst, a cutting-edge nanosynthetic bone graft substitute specifically formulated to stimulate healthy bone tissue formation. Established in 2011, the company maintains its primary operational base in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―